Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 2.10
Ask: 2.15
Change: -0.05 (-2.30%)
Spread: 0.05 (2.381%)
Open: 2.22
High: 2.22
Low: 2.10
Prev. Close: 2.175
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

31 Mar 2020 12:07

RNS Number : 2316I
Immupharma PLC
31 March 2020
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APMKKDBKDBKDONN
Date   Source Headline
24th May 20197:00 amRNSFINAL RESULTS
7th May 20197:00 amRNSCorporate Update
1st Apr 20197:00 amRNSUpdate on Nucant Cancer Programme
14th Mar 20197:00 amRNSCorporate Update
26th Feb 20197:00 amRNSTechnology review published-Nature Communications
31st Dec 20187:00 amRNSClinical Development Collaboration with Incanthera
21st Dec 20184:41 pmRNSSecond Price Monitoring Extn
21st Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 20184:35 pmRNSPrice Monitoring Extension
17th Dec 20187:00 amRNSAppointment of Nominated Adviser
7th Dec 20187:00 amRNSUpdate on Corporate Activities
29th Nov 20184:40 pmRNSSecond Price Monitoring Extn
29th Nov 20184:35 pmRNSPrice Monitoring Extension
28th Nov 20184:40 pmRNSSecond Price Monitoring Extn
28th Nov 20184:35 pmRNSPrice Monitoring Extension
23rd Nov 20184:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20184:35 pmRNSPrice Monitoring Extension
21st Nov 20184:40 pmRNSSecond Price Monitoring Extn
21st Nov 20184:35 pmRNSPrice Monitoring Extension
7th Nov 20184:35 pmRNSPrice Monitoring Extension
1st Nov 20181:38 pmRNSNominated Adviser Status
26th Sep 20187:00 amRNSInterim Results
19th Sep 20187:00 amRNSAppointment of Joint Brokers
7th Sep 20187:00 amRNSCorporate Update
10th Jul 20184:40 pmRNSSecond Price Monitoring Extn
10th Jul 20184:35 pmRNSPrice Monitoring Extension
28th Jun 201812:16 pmRNSResult of AGM
14th Jun 20187:00 amRNSResults of CIDP Pre-Clinical Data
6th Jun 20187:00 amRNSNotice of AGM & Posting of Annual Report
29th May 20187:00 amRNSUpdate on Pivotal Phase III Trial of Lupuzor
29th May 20187:00 amRNSFinal Results
24th Apr 201811:59 amRNSHolding(s) in Company
20th Apr 20188:24 amRNSHolding(s) in Company
19th Apr 20188:05 amRNSHolding(s) in Company
17th Apr 20187:00 amRNSTopline results of Lupuzor Pivotal Phase III Trial
28th Mar 20187:00 amRNSAppointment of Joint Broker
23rd Mar 20187:00 amRNSLupuzor Pivotal Phase III Study Update
5th Mar 20184:13 pmRNSAIM Notice (17)
15th Feb 20187:00 amRNSLondon Investor Evening
9th Feb 20182:00 pmRNSHolding(s) in Company
7th Feb 20189:35 amRNSHolding(s) in Company
5th Feb 20187:00 amRNSHolding(s) in Company
31st Jan 201810:23 amRNSHolding(s) in Company
24th Jan 20187:00 amRNSSuccessful Placing to Raise £10 Million
18th Jan 20187:00 amRNSCompletion of LupuzorT Pivotal Phase III Study
21st Dec 20177:05 amRNSGrant of Options
21st Dec 20177:00 amRNSLast patient completes dosing in LupuzorT Trial
28th Nov 201712:00 pmRNSHolding(s) in Company
24th Nov 20171:32 pmRNSGrant of Options
2nd Nov 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.